Curative Biotechnology Overview
Curative Biotechnology (CUBT) has a P/E ratio of -2.22, below the sector sector average of 33.83.
Get informed when a big investor buys or sells
+ Follow-2.22
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for CUBT is -2.22. That is below the sector sector average of 33.83. Investors often review this figure alongside Curative Biotechnology's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, CUBT currently prints -2.22 for P/E ratio, while the sector average sits near 33.83. That is roughly 106.6% below the sector mean. Large gaps often invite a closer look at Curative Biotechnology's growth, margins, and balance sheet.
A P/E ratio of -2.22 for Curative Biotechnology is not 'good' or 'bad' on its own. Compare it with the peer average (33.83) and with CUBT's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting CUBT's P/E ratio (-2.22), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
